Fate Therapeutics, Inc. (FATE) Balance Sheet

NASDAQ: FATEAssets, liabilities, debt and equity over 10 years.

FATE balance sheet, 2025

December 31, 2025 · U.S. dollars

$318.9M assets = $111.8M liabilities + $207.2M equity

What it owns$318.9MCash & ST investments: $203.7M (63.9%)Cash & ST investments$203.7M · 64%Receivables: $916,000 (0.3%)Other current: $4.1M (1.3%)PP&E: $98.5M (30.9%)PP&E$98.5M · 31%LT investments: $1.5M (0.5%)Other non-current: $10.2M (3.2%)=How it is financed$318.9MCurrent liabilities: $36.1M (11.3%)Current liabilities $36.1MOther LT liabilities: $75.7M (23.7%)Other LT liabilities$75.7M · 24%Shareholders’ equity: $207.2M (65.0%)Shareholders’ equity$207.2M · 65%

Both columns are drawn to the same scale: what FATE owns equals what it owes plus shareholders’ equity. Hover a block for its value.

FATE financial health

Current ratio5.79
Comfortable · current assets cover current liabilities 5.79×
Debt / equity0.38
Low leverage · $0.38 of debt for each $1 of equity
Equity / assets65.0%
Equity-funded · of assets funded by shareholders
Cash / debt261.6%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

FATE balance sheet trends, 2016–2025

Fate Therapeutics, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$95.0M2016$318.9M2025+14.4%/yr
Total liabilities$21.9M2016$111.8M2025+19.9%/yr
Shareholders’ equity$73.2M2016$207.2M2025+12.3%/yr
Cash & short-term investments$92.1M2016$203.7M2025+9.2%/yr
Total debt$10.7M2016$77.8M2025+24.7%/yr
Net cash (debt)$81.4M2016$125.8M2025+$44.4M
Working capital$78.1M2016$172.6M2025+$94.5M
Book value per share$2.302016$1.742025−3.0%/yr
Current ratio6.1420165.792025−0.36
Debt / equity0.1520160.382025+0.23
Shares outstanding31.8M2016118.8M2025+15.8%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

FATE assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

FATE liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

FATE debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

FATE balance sheet

Fate Therapeutics, Inc. annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$203.7M$279.1M$315.2M$436.2M$615.9M$482.9M$221.4M$201.0M$100.9M$92.1M
Cash & equivalents$46.6M$36.1M$41.9M$61.3M$133.6M$167.3M$99.8M$190.5M$89.0M$88.6M
Short-term investments$157.0M$243.0M$273.3M$374.9M$482.3M$315.6M$121.6M$10.5M$12.0M$3.5M
Receivables$916,000$3.5M$1.8M$38.5M$8.7M$5.5M$1.3M$500,000$0$0
Inventory$0$0$0$1$0$1$0$1$0$0
Other current assets$4.1M$9.3M$14.5M$27.4M$8.8M$5.9M$4.3M$3.7M$1.6M$1.2M
Total current assets$208.7M$291.9M$331.5M$502.1M$633.4M$494.3M$227.1M$205.2M$102.6M$93.3M
Property, plant & equipment (net)$98.5M$110.9M$158.5M$66.1M$162.2M$99.4M$22.8M$5.1M$2.5M$1.6M
Goodwill & intangible assets$0$0$0$0$0$0$0$0$0$0
Long-term investments$1.5M$27.7M$980,000$4.9M$100.7M$0$39.4M$0$0$0
Other non-current assets$10.2M$10.2M$15.2M$132.5M$25.1M$28.7M$13.0M$2.7M$146,000$146,000
Total assets$318.9M$440.7M$506.2M$705.6M$921.5M$622.5M$302.3M$213.0M$105.3M$95.0M
Liabilities
Accounts payable$2.7M$9.4M$4.7M$8.3M$8.6M$6.3M$5.8M$4.2M$1.7M$934,000
Short-term debt$4.6M$7.4M$6.2M$5.6M$5.6M$3.4M$1.7M$2.4M$7.3M$8.2M
Deferred revenue$381,000$393,000$685,000$42.2M$21.5M$21.1M$2.8M$7.6M$2.1M$2.1M
Total current liabilities$36.1M$38.5M$39.1M$114.1M$81.3M$85.6M$27.8M$27.3M$11.0M$15.2M
Long-term debt$0$0$0$0$0$0$0$12.4M$14.8M$2.5M
Lease obligations$77.8M$85.3M$103.5M$109.3M$114.8M$97.3M$26.9M———
Other long-term liabilities$75.7M$83.4M$98.7M$107.6M$161.3M$152.4M$29.7M$12.9M$2.2M$4.2M
Total liabilities$111.8M$122.0M$137.8M$221.6M$242.6M$238.0M$57.5M$52.6M$28.1M$21.9M
Shareholders' equity
Common stock & paid-in capital$115,000$114,000$99,000$97,000$96,000$88,000$76,000$65,000$53,000$41,000
Retained earnings (deficit)−$1.53B−$1.40B−$1.21B−$1.05B−$769.1M−$556.9M−$383.5M−$285.4M−$218.8M−$175.8M
Treasury stock————————$0$0
Accumulated other comprehensive income$115,999$268,000$15,000−$1.9M−$762,000$70,000$22,000−$2,000−$3,000−$1,000
Minority interest————————$0$0
Total shareholders' equity$207.2M$318.7M$368.4M$483.9M$678.8M$384.4M$244.8M$160.5M$77.2M$73.2M
Key figures
Total debt$77.8M$85.3M$103.5M$109.3M$114.8M$97.3M$26.9M$14.9M$22.1M$10.7M
Net cash (debt)$125.8M$193.8M$211.6M$326.9M$501.1M$385.6M$194.5M$186.1M$78.9M$81.4M
Working capital$172.6M$253.4M$292.4M$388.0M$552.1M$408.8M$199.3M$177.9M$91.5M$78.1M
Tangible book value$207.2M$318.7M$368.4M$483.9M$678.8M$384.4M$244.8M$160.5M$77.2M$73.2M
Book value per share$1.74$2.80$3.74$5.00$7.16$4.67$3.59$2.86$1.84$2.30
Shares outstanding118.8M113.7M98.4M96.8M94.7M82.4M68.2M56.2M42.0M31.8M
Current ratio5.797.588.484.407.795.788.177.539.296.14
Quick ratio5.677.348.114.167.685.718.017.399.146.07
Debt / equity0.380.270.280.230.170.250.110.090.290.15
Equity / assets65.0%72.3%72.8%68.6%73.7%61.8%81.0%75.3%73.3%77.0%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 26, 2026); data from EODHD.

FATE financial position

At the end of fiscal 2025 (December 31, 2025), Fate Therapeutics had total assets of $318.9 million (down 27.6% from a year earlier), total liabilities of $111.8 million and shareholders' equity of $207.2 million. It held $203.7 million in cash and short-term investments against $77.8 million of debt, a net cash position of $125.8 million. Its current ratio was 5.79. In the latest quarter (ended June 30, 2026) total assets were $260.1 million and equity $153.4 million.

Related: FATE income statement, FATE cash flow statement, FATE key metrics. See the FATE stock overview for the latest quote and news.

FATE balance sheet FAQ

What are Fate Therapeutics's total assets?

Fate Therapeutics reported total assets of $318.9 million at the end of fiscal 2025 (December 31, 2025), compared with $440.7 million a year earlier.

How much debt does Fate Therapeutics have?

Fate Therapeutics had $77.8 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.38.

How much cash does Fate Therapeutics have?

Fate Therapeutics held $203.7 million in cash and short-term investments at the end of fiscal 2025; with $77.8 million of debt that is net cash of $125.8 million.

What is Fate Therapeutics's book value?

Fate Therapeutics's shareholders' equity (book value) was $207.2 million at the end of fiscal 2025, or $1.74 per share.

What is Fate Therapeutics's current ratio?

Fate Therapeutics had current assets of $208.7 million and current liabilities of $36.1 million, a current ratio of 5.79 (it can cover its short-term obligations).

Biotechnology: balance sheet